All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2018-02-26T11:41:40.000Z

Mylotarg (gemtuzumab ozogamicin) given ‘positive opinion’ by the EMA CHMP for use in untreated CD33-positive AML

Feb 26, 2018
Share:

Bookmark this article

On 23 February 2018, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion, recommending the approval of Mylotarg (gemtuzumab ozogamicin) in combination with daunorubicin and cytarabine for the treatment of patients aged 15 years and above with previously untreated  de novo, CD33-positive Acute Myeloid Leukemia (AML), except Acute Promyelocytic Leukemia (APL).1 This positive opinion follows the recent U.S. Food and Drug Administration (FDA) approval of Mylotarg for newly diagnosed and relapsed/refractory CD33-positive AML on 4 September 2017, which was reported here.

Mylotarg, an Antibody Drug Conjugate (ADC), is an antibody-targeted chemotherapeutic agent consisting of a humanized murine CD33 antibody. Since it is a humanized anti-CD33 monoclonal antibody, it is highly specific for targeting leukemic blasts. Mylotarg binds to, and is internalized by tumor cells expressing CD33. As a result, this ADC can then dispense the anti-tumor antibiotic calicheamicin to CD33-expressing tumor cells.2

This recommendation of approval for Mylotarg by the EMA CHMP was based on results from the phase III randomized ALFA-0701 study (NCT00927498), which showed that the combination of Mylotarg with standard chemotherapy regimen in newly diagnosed de novo adult AML patients significantly improved 3-year Event Free Survival (EFS) and Relapse Free Survival (RFS) compared to chemotherapy alone.3

If Mylotarg is approved by the European Commission (EC), the drug manufacturers, Pfizer, highlighted that “the addition of Mylotarg to standard chemotherapy will provide an important new treatment option for patients with AML who would typically be treated with chemotherapy alone”.

  1. Business Wire Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®). 2018 Feb 23. https://www.businesswire.com/news/home/20180223005377/en/Pfizer-Receives-Positive-CHMP-Opinion-Hematology-Medicines [Accessed 2018 Feb 24].
  2. Pagano L. et al. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene. 2007 May 28; 26(25): 3679–3690. DOI: 10.1038/sj.onc.1210364.
  3. Castaigne S. et al. Final Analysis of the ALFA 0701 Study. Blood. 2014; 124: 376.

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
15 votes - 80 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox